Freshly Funded Symic Bio Plays In The Matrix

Emerging Company Profile: Symic Bio recently raised $30m in a Series B financing. CEO Ken Horne talks about the firm's therapeutic focus on the body's extracellular matrix as a therapeutic target, and its two lead programs in peripheral vein graft failure prevention and knee osteoarthritis.

Emerging Company Profile Regular column feature image Version 2

Emeryville, Calif.-based Symic Bio is fresh from a $30m Series B financing and also recently announced updates on its two lead clinical. CEO Ken Horne, a former venture capitalist, joined the firm in 2014 after a biomaterial company he had founded and led was sold to Allergan PLC. He spoke to Scrip about Symic Bio's technology, its development programs and its plans for the future.

Horne explained that in developing synthetic mimics of the macromolecules, or proteoglycans, that regulate the body's extracellular matrix, Symic –...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.